CD8A and neoplasm: A recent phase III clinical study on advanced TNBC showed that the levels of stromal tumour‐infiltrating lymphocytes (sTILs) were correlated with PD‐L1 status, and obvious improvements in the efficacy of immunotherapy were observed only in CD8+ and sTILs+ patients who were also PD‐L1+.40